significant other has received grant/research support from Eisai Inc. and Exelixis Inc. References 1. Gelmon KA Tischkowitz M Mackay H . Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple
Search Results
New Therapies for Ovarian Cancer
Deborah K. Armstrong
Use of PARP Inhibitors for Ovarian Cancer
Presented by: Deborah K. Armstrong
. Swisher EM , Lin KK , Oza AM , . Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial . Lancet Oncol 2017 ; 18 : 75 – 87 . 27908594 8
Practicing What We Preach!
Robert J. Morgan Jr
Bundy BN Alberts DS . Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma . J Clin
Bilateral Risk-Reducing Oophorectomy in BRCA1 and BRCA2 Mutation Carriers
Susan M. Domchek, Jill E. Stopfer, and Timothy R. Rebbeck
ovarian carcinoma after removal of benign ovaries . W V Med J 1993 ; 89 : 282 – 283 . 7. Kemp G Hsiu J Andrews M . Papillary peritoneal carcinomatosis after prophylactic oophorectomy . Gynecol Oncol 1992 ; 47 : 395 – 397 . 8
Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study
Mary Katherine Montes de Oca, Lauren E. Wilson, Rebecca A. Previs, Anjali Gupta, Ashwini Joshi, Bin Huang, Maria Pisu, Margaret Liang, Kevin C. Ward, Maria J. Schymura, Andrew Berchuck, and Tomi F. Akinyemiju
differences in survival among women with ovarian carcinoma . Cancer 2002 ; 94 : 1886 – 1893 . 11920552 10.1002/cncr.10415 5. Bristow RE , Chang J , Ziogas A , Spatial analysis of adherence to treatment guidelines for advanced
Ovarian Clear Cell Carcinoma in Cowden Syndrome
Kevin Yauy, Marion Imbert-Bouteille, Virginie Bubien, Clothilde Lindet-Bourgeois, Gauthier Rathat, Helene Perrochia, Gaëtan MacGrogan, Michel Longy, Didier Bessis, Julie Tinat, Stéphanie Baert-Desurmont, Maud Blanluet, Pierre Vande Perre, Karen Baudry, Pascal Pujol, and Carole Corsini
cancer-related death in women. 8 Among major histologic subtypes, OCCC, a distinct subtype of epithelial ovarian cancer, is the second most common ovarian carcinoma. 9 , 10 OCCC is rarely bilateral, and patients are usually diagnosed at an early stage
Ovarian Cancer, Version 3.2012
Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes, and Mary A. Dwyer
HH Lin Y . Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas . Cancer Res 2005 ; 65 : 2162 – 2169 . 9 Nolen B Velikokhatnaya L Marrangoni A . Serum biomarker
Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy
Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl
JK , Teoh D , Hu JM , . Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers . Gynecol Oncol 2008 ; 109 : 370 – 376 . 18395777 10.1016/j.ygyno.2008
Optimizing Ovarian Cancer Treatment and Prevention Through Parallel Germline and Somatic Genetic Testing
Janice S. Kwon
, Harrell MI , Brady MF , Inherited mutations in women with ovarian carcinoma . JAMA Oncol 2016 ; 2 : 482 – 490 . 5. Kuchenbaecker KB , Hopper JL , Barnes DR , Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and
Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of Heterozygosity
Alice Zhou, Omar Butt, Michael Ansstas, Elizabeth Mauer, Karam Khaddour, and George Ansstas
ovarian carcinoma . Sci Rep 2020 ; 10 : 2757 . 32066851 18. Khaddour K , Ansstas M , Visconti J , Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and
